Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -141.65 is 522% below its 5-year average of -22.76, near the low end of its 5-year range (-141.65–-13.21).
595.56% below its 12-month average of -20.37.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.84.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 23 comparable quarters.
EARNINGS PER SHARE (EPS)
-141.65
EARNINGS PER SHARE (EPS) AVG TTM
-20.37
EARNINGS PER SHARE (EPS) AVG 3Y
-24.20
EARNINGS PER SHARE (EPS) AVG 5Y
-22.76
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-595.56%
CURRENT VS 3Y AVG
-485.45%
CURRENT VS 5Y AVG
-522.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Faeth Therapeutics, Inc.
Market Cap
$698.60M
Earnings Per Share (EPS)
-141.65
TTM Avg
-20.37
3Y Avg
-24.20
5Y Avg
-22.76
Market Cap
$707.86M
Earnings Per Share (EPS)
-5.51
TTM Avg
-4.06
3Y Avg
-4.55
5Y Avg
-6.70
Market Cap
$688.14M
Earnings Per Share (EPS)
-1.16
TTM Avg
-1.18
3Y Avg
-1.68
5Y Avg
-2.29
Market Cap
$709.33M
Earnings Per Share (EPS)
1.24
TTM Avg
2.06
3Y Avg
1.25
5Y Avg
1.30
Market Cap
$719.64M
Earnings Per Share (EPS)
-1.55
TTM Avg
-1.25
3Y Avg
-1.99
5Y Avg
-2.90
Market Cap
$675.41M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
Market Cap
$734.10M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
Market Cap
$749.55M
Earnings Per Share (EPS)
-1.41
TTM Avg
-1.23
3Y Avg
-0.97
5Y Avg
-1.16
Market Cap
$643.37M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $698.60M | -141.65 | -20.37 | -24.20 | -22.76 |
| Helus Pharma Inc. (HELP)vs › | $707.86M | -5.51 | -4.06 | -4.55 | -6.70 |
| Annexon, Inc. (ANNX)vs › | $688.14M | -1.16 | -1.18 | -1.68 | -2.29 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 1.24 | 2.06 | 1.25 | 1.30 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -1.55 | -1.25 | -1.99 | -2.90 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -2.72 | -2.70 | -2.77 | -2.61 |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -2.76 | -3.16 | -2.11 | -1.54 |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -1.41 | -1.23 | -0.97 | -1.16 |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -1.78 | -1.75 | -1.85 | -1.69 |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -0.88 | -0.85 | -1.91 | -1.52 |
Trailing EPS (TTM)
$-141.65
Forward EPS (Est.)
$-15.07
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -16.72 |
| 2024-12-31 | -24.01 |
| 2023-12-31 | -24.40 |
| 2022-12-31 | -31.65 |
| 2021-12-31 | -26.56 |
| 2020-12-31 | -13.21 |
| 2019-12-31 | -14.01 |
| 2018-12-31 | -11.49 |
